PMC-309


Indications: Solid tumors


PMC-309 is an engineered monoclonal antibody that targets the negative immune checkpoint human VISTA (V-domain Ig suppressor of T cell activation).



Mechanism of action / Target

PMC-309 binds to VISTA expressing cells such as myeloid-derived suppressor cells (MDSC) that inhibits VISTA-mediated T cell inactivation and proliferation.


Status

The discovery of preclinical efficacy and mechanism of action is in progress using human VISTA-KI model in mice. The production of samples needed for the GLP-toxicity study is underway for the IND filing.


LinkedIn  I   Facebook  I  YouTube



    • 2F, Research Building 2, 70, Yuseong-daero 1689 beon-gil,
      Yuseong-gu, Daejeon, 34047, Republic of Korea
    • HQ +82-42-863-2017
    • R&D Center +82-42-861-2017
    • FAX +82-42-863-2080
  • COPYRIGHT BY PharmAbcine Inc. ALL RIGHTS RESERVED.